Work

Axitinib vs Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors

Year: 2012

Type: article

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)33351-2

Authors: R.J. Motzer, B. Escudier, P. Tomczak, S. Negrier, M.E. Gore, J. Tarazi, S. Hariharan, B. Rosbrook, S. Kim, B.I. Rini

Institutions: Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Fondation Gustave Roussy, Poznan University of Medical Sciences, Centre Léon Bérard, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Pfizer (United States), Cleveland Clinic

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3000704408

FWCI: 2.845

Cites:

Cited by: 13

Related to: 10